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etter growth characteristics than IC-E122G and IC-D277A.
he reproduction of IC-E122G and IC-D277A in fasting ticks
as similar to that of control HA positive virus whereas
he titres of IC-D67G were signiﬁcantly lower (2.5-3 vs. 1-2
og10PFU/ml, respectively). In feeding ticks, the titre of IC-
122G increased approximately 1000-fold and IC-D277A and
C-D67G - approximately 300-fold, whereas for control virus
he increase was about 10-fold. Non-viraemic transmission
fﬁciency from infected to uninfected ticks was increased
y each individual substitution in nymphal I. ricinus (Figure
).
igure 1 Tick-to-tick transmission rate (clear bars) is
xpressed as the proportion of infected I.ricinus nymphs.
lack triangles show the average virus titres in individu-
lly infected recipient nymphs as determined by plaque
ssay.
Conclusion: We hypothesize that the mechanism
f adaptation of TBEV to its host utilizes the shift of
harge/hydrophobicity at several critical aminoacid
esidues exposed on the virion surface. This shift results in
ifferent biological consequences depending on the local-
sation of certain aminoacid residue. The results provide
aluable information concerning the maintenance in nature
nd the emergence of pathogenic variants of TBEV.
oi:10.1016/j.ijid.2010.02.1589
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pre-exposure prophylactic for arenaviral hemorrhagic
ever in the pirital virus-Syrian golden hamster model
. Vela ∗, R. Stammen, J. Garver, S. Sarrazine
Battelle, Columbus, OH, USA
Background: Arenaviral infections in humans have the
apacity to lead to hemorrhagic fever and may be fatal.
upportive care and ribavirin remain the only options for
renaviral infections in humans; however, treatment is often
neffective because of the time frame before the disease is
ecognized. Pirital virus (PIRV) is a New World arenavirus
hat was isolated from the cotton rat (Sigmodon alstoni) in
he Municipality of Guanarito, Portuguesa State, Venezuela
n 1994. This virus is not associated with any form of disease
n humans and can be studied in a biosafety level 3 (BSL-
) laboratory environment; therefore, the development of
small animal model system is ideal for testing and/or
creening of vaccines and therapeutics against arenavirus
emorrhagic fever.
t
s
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Methods: Treated andmock-treated female Syrian golden
mplanted with telemetry units measuring temperature and
ctivity, were utilized to test the antiviral effects of the
ompound named BAT-V1. The animals were followed for
4 days post-challenge. Clinical signs of disease were mon-
tored. Temperatures and acitivty levels were recorded by
elemetry. Clinical chemistry, hematology, and coagulation
arameters were measured and viral titers in the tissues and
lood were analyzed.
Results: We demonstrate that PIRV infection in Syrian
olden hamsters leads to morbidity, fever, lethargy, hem-
rrhagic fever manifestations, viremia, and replication in
elect tissues and results in 100% mortality within 8 days
fter challenge. Treating hamsters with BAT-V1 prior to chal-
enge signiﬁcantly protected the animals from death, which
s important because survival of hamsters infected with PIRV
as not previously been reported. Abnormal temperatures,
ematology, clinical chemistry, and coagulation parameters
ssociated with PIRV infection in hamsters all rebounded to
ormal levels in the treated animals. Lower viremia and inhi-
ition of viral replication in select tissues were also observed
n treated animals when compared to mock-treated animals.
Conclusion: Results from this study demonstrate a BSL-
arenaviral hemorrhagic fever animal model that can be
tilized to test and screen multiple antivirals in a time
fﬁcient and cost effective manner. Additionally, the data
emonstrate pre-exposure protective efﬁcacy of an antiviral
gainst PIRV-induced hemorrhagic fever in the Syrian golden
amster model.
oi:10.1016/j.ijid.2010.02.1590
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haracterization of a novel neutralizing monoclonal
ntibody that recognizes the fusion loop of Flavivirus
nvelope protein
. Deng1, G. Ji 2, Y. Kang2, T. Jiang1, J. Dai2, E. Qin1, Y.
uo2, C. Qin1,∗
Beijing Institute of Microbiology and Epidemiology, Bei-
ing, China
International Joint Cancer Institute, Second Military Med-
cal University, Shanghai, China
Background: Dengue, West Nile and yellow fever viruses
re major human pathogens that belong to the Flavivirus
enus, and cause large epidemics and deaths worldwide.
iven the lack of approved antiviral treatment, recombi-
ant monoclonal antibodies (MAbs) have been veriﬁed as
andidate for the treatment of ﬂavivirus infections.
Methods: A panel of MAbs against dengue 2 virus was
roduced according to the standard procedure. Indirect
mmunoﬂuorescence assay and ELISA were performed to
dentify the cross-reactivity against ﬂaviviruses. In vitro
ndin vivo experiments were performed to analyze the neu-
ralizing and protection proﬁles of a selected MAb against
engue and other ﬂavivirus. Epitope mapping and in vitro
inding inhibition assays were further carried out to charac-
erize this speciﬁc MAb.
Results: Plaque reduction neutralization test demon-
trated that MAb 2A10G6 was active to neutralize dengue
-4, yellow fever and West Nile viruses. In vivo protection
